BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Advanced Malignant Solid Neoplasm Clinical Trial

Official title:

Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04021043
• Other study ID #: 2018-0419
• Secondary ID: NCI-2019-0040520
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: August 19, 2019
• Est. completion date: August 29, 2024

Study information

• Verified date: January 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung/chest or liver cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving BMS-986156, ipilimumab, and nivolumab with or without stereotactic body radiation therapy will work better in treating patients with lung/chest or liver cancers.

Description:

PRIMARY OBJECTIVES: I. To determine the safe dose of BMS-986156 and dose limiting toxicities (DLT) (30 mg versus [vs] 100 mg) when combined with ipilimumab (3 mg/kg) for patients with metastatic cancer. II. To evaluate the safety and toxicity profile of ipilimumab (3mg/kg) with BMS-986156 (30 or 100 mg) administered in combination with stereotactic body radiation therapy (SBRT) targeting 1-4 LIVER lesion(s) for patients with metastatic cancers. III. To evaluate the safety and toxicity profile of ipilimumab (3mg/kg) with BMS-986156 (30 or 100 mg) administered in combination with SBRT targeting 1-4 LUNG lesion(s) for patients with metastatic cancer. IV. To determine safety and toxicity profile of nivolumab (480 mg) with BMS-986156 (30 mg) administered in combination with SBRT targeting 1-4 LIVER lesion(s) for patients with metastatic cancers. V. To determine safety and toxicity profile of nivolumab (480 mg) with BMS-986156 (30 mg) administered in combination with SBRT targeting 1-4 LUNG lesion(s) for patients with metastatic cancers. SECONDARY OBJECTIVES: I. To determine antitumor activity of ipilimumab therapy with BMS-986156 (30 or 100 mg) as well as nivolumab with BMS-986156 (30 mg) with SBRT treatment for 1-4 lung lesions in both the SBRT treated lesion and non-irradiate tumors. II. To determine antitumor activity of ipilimumab therapy with or without BMS-986156 (30 or 100 mg) as well as nivolumab with BMS-986156 (30 mg) with SBRT treatment for 1-4 liver lesions in both the SBRT treated lesion and non-irradiate tumors. III. To compare response and progression of the non-irradiated tumors between BMS-986156 with ipilimumab vs BMS-986156 with nivolumab, using both immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) version (V) 1.1. IV. To evaluate the predictive potential value of tumor-associated and systemic immune biomarkers for therapy effectiveness and toxicity prediction. V. To evaluate whether skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor bulk are correlated with clinical outcomes and adverse events. VI. To evaluate whether tumor kinetics in combination with clinical correlates can help determine treatment response. VII. To evaluate whether tumor mutational burden correlates with improved clinical outcomes and response criteria. OUTLINE: This is a phase I, dose-escalation study of anti-GITR agonistic monoclonal antibody BMS-986156, followed by a phase II study. Patients are assigned to 1 of 3 groups. GROUP I: Patients receive ipilimumab intravenously (IV) over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. GROUP II: Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. GROUP III: Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, then every 2-4 months for up to 1 year.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 68
• Est. completion date: August 29, 2024
• Est. primary completion date: August 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histological confirmation of solid metastatic cancer with at least one metastatic or primary lesion in the liver or lung/chest, except for group 1.
• Patients who have completed prior systemic anti-cancer therapies, an interval of 5 drug half-lives or 4-weeks whichever is shorter, is required, prior to enrollment on study. Note: patients with anaplastic thyroid will be waived from this inclusion criteria given the rapid trajectory of their disease
• All patients must have at least one metastatic or primary lesion within the lung/chest or liver located in an anatomical location amenable to SBRT treatment with 50 Gy in 4 fractions or with 60 Gy in 10 fractions, except for group 1.
• Repeat radiation in fields previously radiated will be allowed at the discretion of the treating physician
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky > 60%)
• Total bilirubin =< 2.0 mg/dL (does NOT apply to patients with Gilbert's syndrome) (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
• White blood count (WBC) >= 2500/uL (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
• Absolute neutrophil count (ANC) >= 1000/uL (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
• Platelets >= 75K (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
• Hemoglobin >= 9 g/dL (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
• Creatinine =< 2.0 x upper limit of normal (ULN) (use of growth factors or blood transfusion to achieve these requirements is not allowed 2 weeks prior to study enrollment)
• Patients must be willing and able to review, understand, and provide written consent before starting therapy
• Patients with brain metastasis will be included as long as they are free of neurologic symptoms related to metastatic brain lesions and who do not require or receive systemic corticosteroid therapy, > 10 mg/day in the 14 days prior to beginning the trial (=< 10 mg steroid, e.g.: prednisone, is allowed). Patients with stable brain metastases (clinically and radiographically) for >= 4 weeks to enroll on the protocol.
• Patients that have previously progressed on immunotherapy such as ipilimumab, anti-PD-I, anti-PDL-1 or talimogene laherparepvec (T-VEC) will be eligible.

Exclusion Criteria:

• Serious autoimmune disease at the discretion of the treating attending: patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune vasculitis (e.g., Wegener's granulomatosis) are excluded from this study
• Active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation
• Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events (AEs): e.g. a condition associated with frequent diarrhea or chronic skin conditions, recent surgery or colonic biopsy from which the patient has not recovered, or partial endocrine organ deficiencies
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, history of congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has not been documented to be stable
• Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab)
• Concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids while receiving ipilimumab (as long as steroid replacement is significantly greater than what is required for physiologic replacement, i.e. in hypothyroidism)
• Pregnant women are excluded from this study. Women of child-bearing potential (WOCBP) must have a pregnancy test every 4 weeks and WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of immunotherapy drugs (ipilimumab/nivolumab/BMS-986156), during the course of the treatment and 160 days AFTER the last dose of study drug you should not get pregnant or breast feed. In the case of male participants, during the course of treatment and 220 days AFTER the last dose of immunotherapy you should not father a child (condom use is mandatory, even if vasectomized) or donate sperm. For contraception guidelines please see protocol
• History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
• Prior allogeneic stem cell transplantation
• Patients who were intolerant to previous immuno-oncology (IO) drugs should be excluded

Related Conditions & MeSH terms

• Advanced Malignant Solid Neoplasm
• Carcinoma
• Metastatic Carcinoma in the Liver
• Metastatic Carcinoma in the Lung
• Metastatic Malignant Neoplasm in the Thoracic Cavity
• Metastatic Malignant Solid Neoplasm
• Neoplasms

Intervention

Drug:
• Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Given IV

Biological:
• Ipilimumab
Given IV
• Nivolumab
Given IV

Radiation:
• Stereotactic Body Radiation Therapy
Undergo SBRT

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicities (DLT)	Descriptive statistics will be computed.	Up to 29 days for groups 1 and 3, up to day 43 for group 2
Primary	Incidence of adverse events of ipilimumab with anti-GITR agonistic monoclonal antibody BMS-986156 (BMS-986156) and stereotactic body radiation therapy (SBRT) targeting liver lesions	Will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 versus (vs.) treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.	Up to 1 year
Primary	Incidence of adverse events of ipilimumab with BMS-986156 and SBRT targeting lung lesions	Will be assessed using CTCAE version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 vs. treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.	Up to 1 year
Primary	Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting liver lesions	Will be assessed using CTCAE version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 vs. treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.	Up to 1 year
Primary	Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting lung lesions	Will be assessed using CTCAE version 4.0. Descriptive statistics will be computed. Safety will be compared in two separate analyses among different treatment regimens: treatment group 1 vs. treatment group 2, treatment group 2 vs. treatment group 3, and among different SBRT targets liver vs lung: treatment group 2 vs. treatment group 3.	Up to 1 year
Secondary	Treatment Success Defined by Immune-related Responses	Assessment of antitumor activity of ipilimumab & nivolumab with BMS-986156 & SBRT for 1-4 lung lesions in both SBRT treated lesion and non-irradiate tumors where treatment success defined as immune-related complete response (irCR) or immune-related partial response (irPR) or immune-related stable disease (irSD), assessed using immune-related response criteria (irRC) (e.g. the best response obtained by a patient).irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden =50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden =25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation.	Up to 1 year
Secondary	Treatment Success Defined by Immune-related Responses	Assessment of antitumor activity of ipilimumab with or without BMS-986156 as well as nivolumab with BMS-986156 with SBRT treatment for 1-4 liver lesions in both the SBRT treated lesion and non irradiate tumors where treatment success defined as irCR or irPR or irSD, assessed using irRC (e.g. the best response obtained by a patient).irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden =50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden =25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation. Clinical benefit established as having irSD for up to 6 months for irSD.	Up to 1 year
Secondary	Response of non-irradiated tumors	Comparison of response of non-irradiated tumors between BMS-986156 with ipilimumab vs BMS-986156 with nivolumab done using irRc (e.g. the best response obtained by a patient).irRc efined as irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden =50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden =25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; ; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation. Clinical benefit established as having irSD for up to 6 months for irSD.Comparisons between groups will be assessed with regard to the irRC outcomes.	Up to 1 year
Secondary	Predictive potential value of tumor-associated and systemic immune biomarkers	For the predictive potential value of tumor-associated and systemic immune biomarkers, comparisons will be performed between group 2 (Ipilimumab plus BMS-986156 with SBRT) and group 3 (Nivolumab plus BMS-986156 with SBRT) per treatment site (liver or lung). Potential values may be summarized as qualitative or descriptive lists.	Up to 1 year
Secondary	Adverse events will be evaluated using skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor bulk.	It will be evaluated whether skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor bulk are correlated with clinical outcomes and adverse events.Correlation may be summarized as qualitative or descriptive list of item's possible association to clinical outcome and/or adverse event.	Up to 1 year
Secondary	Treatment response	It will be evaluated whether tumor kinetics in combination with clinical correlates can help determine treatment response. The radiological response and clinical data will be analyzed using mathematical and statistical models to identify prognostic groups.	Up to 1 year
Secondary	Tumor mutational burden	Will be correlated with improved clinical outcomes and response criteria.	Up to 1 year
Secondary	Progression of non-irradiated tumors	Comparison of progression of non-irradiated tumors between BMS-986156 with ipilimumab vs BMS-986156 with nivolumab done using irRc where treatment success defined as Response Evaluation Criteria in solid Tumors (RECIST) version 1.1: Complete Response (CR): Disappearance all target lesions; Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): At least 20% increase in sum LD target lesions, reference smallest sum LD recorded since treatment started or appearance 1/> new lesions; Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD, reference smallest sum LD since treatment started	Up to 1 year

External Links

•   MD Anderson Cancer Center